Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
GAITHERSBURG, Md., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Jeffrey Stoddard, M.D., to the position of Vice President, Medical Affairs. Dr. Stoddard’s efforts will be focused on external engagement with thought leaders, vaccine experts, policymakers and key stakeholders. He will also be responsible for evidence generation related to health economics and outcomes research.
Dr. Stoddard joins Novavax with more than 15 years of vaccine research and development experience and leadership roles. He was instrumental in the commercial launch of multiple vaccines and biologics including Synagis®, FluMist®, pandemic flu vaccines, Menveo® and Bexsero®. He was most recently Vice President, Medical Affairs & Medical Professional Services, at Alkermes plc, where he led medical affairs, and health economics and outcomes research. Prior to Alkermes, Dr. Stoddard held positions of increasing responsibility at Novartis Vaccines, Covance and MedImmune. Dr. Stoddard earned his medical degree from the University of Wisconsin Medical School, a Bachelor of Science degree from the University of Wisconsin-Madison, and completed a residency at Johns Hopkins Hospital and a postdoctoral fellowship in the Pew Health Policy program at the University of California, San Francisco.
“Dr. Stoddard is a foundational building block of the Novavax commercial team,” said John Trizzino, Senior Vice President, Commercial Operations. “His medical and healthcare policy experience will be critical as we develop our disease state awareness and vaccine policy strategy and we look forward to his leadership in educating healthcare providers in anticipation of the commercial launch of our respiratory syncytial virus F-protein nanoparticle vaccine candidate.”
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company’s website, novavax.com.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Senior Manager, Investor Relations [email protected] 240-268-2000 Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] [email protected] 212-845-4271
